Moderna's COVID-19 vaccine candidate meets its primary efficacy endpoint in the first interim analysis of the Phase 3 COVE study
18 Nov 2020

Moderna's COVID-19 vaccine candidate meets its primary efficacy endpoint in the first interim analysis of the Phase 3 COVE study

https://www.worldpharmanews.com/business/5473-moderna-s-covid-19-vaccine-candidate-meets-its-primary-efficacy-endpoint-in-the-first-interim-analysis-of-the-phase-3-cove-study